Results 171 to 180 of about 96,164 (192)

Mitochondrial injury in steatohepatitis

European Journal of Gastroenterology & Hepatology, 2004
Rich diet and lack of exercise are causing a surge in obesity, insulin resistance and steatosis, which can evolve into steatohepatitis. Patients with non-alcoholic steatohepatitis have increased lipid peroxidation, increased tumour necrosis factor-alpha (TNF-alpha) and increased mitochondrial beta-oxidation rates. Their in-vivo ability to re-synthesize
Dominique, Pessayre, Bernard, Fromenty, Abdellah, Mansouri   +2 more
openaire   +2 more sources

Pathogenesis of steatohepatitis

Best Practice & Research Clinical Gastroenterology, 2002
Understanding the pathogenesis of non-alcoholic steatohepatitis has recently assumed great importance with the recognition that it has the potential to progress to fibrosis and cirrhosis. The 'two-hit' model of pathogenesis was proposed in 1998, with the first 'hit' - steatosis - increasing the sensitivity of the liver to the second 'hits' mediating ...
openaire   +3 more sources

Steatohepatitis in children

Best Practice & Research Clinical Gastroenterology, 2002
Steatohepatitis in children occurs in the childhood version of non-alcoholic fatty liver disease (NAFLD), as a result of hepatotoxicity and with certain genetic/metabolic diseases. Until recently, NAFLD was considered to be rare in children. It is now recognized as an important childhood liver disease, especially because childhood obesity is much more ...
openaire   +2 more sources

Drug-induced steatohepatitis

Clinics in Liver Disease, 2003
Drugs rarely cause steatohepatitis, but amiodarone, perhexiline, and DH, have unequivocally been found to independently induce the histologic picture of alcoholic liver disease or NASH. All three agents have similar pathogenetic mechanisms of hepatotoxicity, targeting mitochondrial ATP production and fatty acid catabolism. Other drugs that occasionally
R Todd, Stravitz, Arun J, Sanyal
openaire   +2 more sources

Drugs and Steatohepatitis

Seminars in Liver Disease, 2002
In addition to the usual associations with insulin resistance, type 2 diabetes, central obesity, and hypertriglyceridemia, nonalcoholic steatohepatitis (NASH) has been associated with several drugs and toxins. However, drug-induced liver disease is a relatively uncommon cause of steatohepatitis.
openaire   +2 more sources

Nonalcoholic Steatohepatitis in Children

Journal of Pediatric Gastroenterology and Nutrition, 2000
ABSTRACTBackground:Nonalcoholic steatohepatitis occurs commonly in adults with obesity or diabetes mellitus. There are only a few reports of this condition in children.Methods:Prospective consecutive clinical series.Results:Between December 1985 and April 1995, 36 children (21 boys, 15 girls) were diagnosed with nonalcoholic steatohepatitis at the ...
M, Rashid, E A, Roberts
openaire   +2 more sources

Steatohepatitis in obese individuals

Best Practice & Research Clinical Gastroenterology, 2002
Nonalcoholic steatohepatitis (NASH), which is the most severe histological form of nonalcoholic fatty liver disease (NAFLD), is emerging as the most common clinically important form of liver disease in developed countries. Although its prevalence is 3% in the general population, this increases to 20-40% in obese patients.
Wael I, Youssef, Arthur J, McCullough
openaire   +2 more sources

Inflammation and fibrogenesis in steatohepatitis

Journal of Gastroenterology, 2012
Nonalcoholic fatty liver disease consists of a range of disorders characterized by excess accumulation of triglyceride within the liver. Whereas simple steatosis is clinically benign, nonalcoholic steatohepatitis (NASH) often progresses to cirrhosis.
Hideki, Fujii, Norifumi, Kawada
openaire   +2 more sources

Non-alcoholic Steatohepatitis in Children

Clinics in Liver Disease, 2003
Non-alcoholic steatohepatitis (NASH) is an important liver disease in children; it can cause cirrhosis in children. The disease mechanism involves hepatic insulin resistance with hyperinsulinemia and changes in certain adipocytokines and inflammatory mediators.
openaire   +3 more sources

Animal models of steatohepatitis

Best Practice & Research Clinical Gastroenterology, 2002
Animal models of hepatic steatosis and steatohepatitis have improved our understanding of the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Three models, genetically obese ob/ob mice, lipoatrophic mice and normal rats fed choline-deficient, methionine-restricted diets, have been particularly informative.
Ayman, Koteish, Anna, Mae Diehl
openaire   +2 more sources